Rachel score: a nomogram model for predicting the prognosis of lung neuroendocrine tumors

被引:3
|
作者
La Salvia, A. [1 ,2 ]
Marcozzi, B. [3 ,4 ]
Manai, C. [1 ]
Mazzilli, R. [5 ]
Landi, L. [1 ]
Pallocca, M. [3 ]
Ciliberto, G. [6 ]
Cappuzzo, F. [1 ]
Faggiano, A. [5 ]
机构
[1] IRCCS Regina Elena Natl Canc Inst, Med Oncol 2, Rome, Italy
[2] Natl Inst Hlth ISS, Natl Ctr Drug Res & Evaluat, Rome, Italy
[3] IRCCS Regina Elena Natl Canc Inst, Biostat Bioinformat & Clin Trial Ctr, Rome, Italy
[4] Natl Inst Hlth ISS, Cardiovasc Endocrine Metab Dis & Aging, Rome, Italy
[5] Sapienza Univ Rome, ENETS Ctr Excellence, St Andrea Univ Hosp, Dept Clin & Mol Med, Rome, Italy
[6] IRCCS Regina Elena Natl Canc Inst, Sci Direct, Rome, Italy
关键词
Neuroendocrine tumors; Lung NET; Primary tumor location; Nomogram; Prognostic score; CARCINOID-TUMORS; SURVIVAL; VALIDATION;
D O I
10.1007/s40618-024-02346-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Lung NET, classified in typical carcinoids (TC) and atypical carcinoids (AC), are highly heterogeneous in their biology and prognosis. The histological subtype and TNM stage are well-established prognostic factors for lung NET. In a previous work by our group, we demonstrated a significant impact of laterality on lung NET survival outcomes. Materials and methods We developed a nomogram that integrates relevant prognostic factors to predict lung NET outcomes. By adding the scores for each of the variables included in the model, it was possible to obtain a prognostic score (Rachel score). Wilcoxon non-parametric statistical test was applied among parameters and Harrell's concordance index was used to measure the models' predictive power. To test the discriminatory power and the predictive accuracy of the model, we calculated Gonen and Heller concordance index. Time-dependent ROC curves and their area under the curve (AUC) were used to evaluate the models' predictive performance. Results By applying Rachel score, we were able to identify three prognostic groups (specifically, high, medium and low risk). These three groups were associate to well-defined ranges of points according to the obtained nomogram (I: 0-90, II: 91-130; III: > 130 points), providing a useful tool for prognostic stratification. The overall survival (OS) and progression free survival (PFS) Kaplan-Meier curves confirmed significant differences (p < 0.0001) among the three groups identified by Rachel score. Conclusions A prognostic nomogram was developed, incorporating variables with significant impact on lung NET survival. The nomogram showed a satisfactory and stable ability to predict OS and PFS in this population, confirming the heterogeneity beyond the histopathological diagnosis of TC vs AC.
引用
收藏
页码:2575 / 2586
页数:12
相关论文
共 50 条
  • [31] A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
    Osher, Esther
    Shalabna, Eiman
    Klausner, Joseph M.
    Greenman, Yona
    Stern, Naftali
    Shibolet, Oren
    Scapa, Erez
    Yakir, Oz
    Shor, Dana Ben-Ami
    Bar-Yishay, Iddo
    Shamai, Sivan
    Sofer, Yael
    Lubezky, Nir
    Goykhman, Yaacov
    Lahat, Guy
    Wolf, Ido
    Pelles, Sharon
    Aizic, Asaf
    Blachar, Arye
    Geva, Ravit
    BIOMEDICINES, 2023, 11 (02)
  • [32] A Predictive Nomogram for Small Intestine Neuroendocrine Tumors (NETS)
    Kelly, Susheian
    Aalberg, Jeffrey
    Kim, Michelle
    Divino, Celia
    PANCREAS, 2019, 48 (03) : 441 - 441
  • [33] Biomarkers for prognosis in pancreatic neuroendocrine tumors
    Zhu, Mojun
    Sorenson, Karl R.
    Liu, Rebecca
    Rothberg, Bonnie E. Gould
    Halfdanarson, Thorvardur R.
    ENDOCRINE-RELATED CANCER, 2021, 28 (12) : 773 - 782
  • [34] Pathology and Diagnosis of Neuroendocrine Tumors: Lung Neuroendocrine
    Travis, William D.
    THORACIC SURGERY CLINICS, 2014, 24 (03) : 257 - +
  • [35] Validated Risk-Score Model Predicting Lymph Node Metastases in Patients with Non-Functiona Gastroenteropancreatic Neuroendocrine Tumors
    Shannon, Adrienne B.
    Straker, Richard J., III
    Fraker, Douglas L.
    Miura, John T.
    Karakousis, Giorgos C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2022, 234 (05) : 900 - 909
  • [36] RETRACTED: A Nomogram Predicting the Prognosis of Renal Cell Carcinoma Patients with Lung Metastases (Retracted Article)
    Sheng, Xinyu
    Lu, Xuan
    Wu, Jian
    Chen, Lu
    Cao, Hongcui
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [37] Theranostics in Lung Neuroendocrine Tumors
    Dev, Indraja D.
    Puranik, Ameya D.
    Trikalinos, Nikolaos A.
    Girod, Bradley John
    Kim, Hyun
    Prasad, Vikas
    SEMINARS IN NUCLEAR MEDICINE, 2025, 55 (02) : 221 - 233
  • [38] Neuroendocrine Tumors of the Lung An Update
    Rekhtman, Natasha
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2010, 134 (11) : 1628 - 1638
  • [39] The Evolution of Lung Neuroendocrine Tumors
    Alcala, N.
    Dayton, T.
    Di Genova, A.
    Sexton-Oates, A.
    Voegele, C.
    Damiola, F.
    Tabone-Eglinger, S.
    Mangiante, L.
    Mathian, E.
    Girard, N.
    Lantuejoul, S.
    Clevers, H.
    Fernandez-Cuesta, L.
    Foll, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S46 - S47
  • [40] Advances in neuroendocrine lung tumors
    Travis, W. D.
    ANNALS OF ONCOLOGY, 2010, 21 : 65 - 71